At 3 p.m., European countries will know whether it is reasonable to use Johnson & Johnson's vaccine against Covid-19.
It is indeed at this time, this Tuesday, that the European Medicines Agency (EMA) will give its opinion on the vaccine called Janssen.
The Amsterdam-based EMA will give its analyzes during a "virtual press conference on the conclusions about the safety assessment" of this single-dose vaccine.
Its use is currently suspended in the United States and Europe due to the rare occurrence of serious blood clots.
Thrombosis worries
US health authorities recommended on April 13 "a pause" in the use of the Johnson & Johnson vaccine to investigate the occurrence of serious cases of blood clots in several people in the United States.
That suspension was extended the next day by at least a week, after a panel of experts said they needed more time to investigate the matter.
The American pharmaceutical group Johnson & Johnson, for its part, let it be known that it had "taken the decision to delay the deployment" of its vaccine against Covid-19 in Europe after the recommendation on the "pause" in its use in the United States. United.
A person died of blood thrombosis in the United States after receiving this vaccine, an official of the United States Medicines Agency (FDA) announced on April 13.
Six cases of women who developed severe cases of blood clots in association with low platelet levels after receiving Johnson & Johnson have been reported in the United States.
However, the use of this vaccine should be re-authorized in the United States, perhaps accompanied by "restrictions", and a decision should be made public by Friday, the White House medical adviser said on Sunday. Anthony Fauci.
Health
The WHO emergency committee opposes a compulsory vaccination passport for travel
Health
The Indian variant should be "watched", but should not be a source of anxiety
Video
Covid 19
Janssen
Coronavirus
Health
Vaccine
Vaccination